12.47
1.01 (8.81%)
| Previous Close | 11.46 |
| Open | 11.56 |
| Volume | 2,044,627 |
| Avg. Volume (3M) | 3,883,573 |
| Market Cap | 1,174,918,784 |
| Price / Book | 10.22 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2026 |
| Diluted EPS (TTM) | -3.07 |
| Total Debt/Equity (MRQ) | 18.32% |
| Current Ratio (MRQ) | 7.95 |
| Operating Cash Flow (TTM) | -192.25 M |
| Levered Free Cash Flow (TTM) | -110.31 M |
| Return on Assets (TTM) | -31.26% |
| Return on Equity (TTM) | -62.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Replimune Group, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| Macro Environment | 0.0 |
| AI Insight | NA |
| Weighted Average | 0.25 |
Select this tab to load the latest available analysis.
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.51% |
| % Held by Institutions | 107.50% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ridgeback Capital Investments L.P. | 30 Jun 2026 | 7,310,656 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Aug 2026 | CNBC | HHS plans new FDA deputy commissioner roles for technology and drugs, sources say |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |